Clal Insurance Enterprises Holdings Ltd Has $621.34 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Clal Insurance Enterprises Holdings Ltd grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 34,543,812 shares of the company’s stock after purchasing an additional 2,204,623 shares during the quarter. Teva Pharmaceutical Industries makes up approximately 5.5% of Clal Insurance Enterprises Holdings Ltd’s portfolio, making the stock its 4th biggest position. Clal Insurance Enterprises Holdings Ltd owned 3.05% of Teva Pharmaceutical Industries worth $621,337,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Coronation Fund Managers Ltd. bought a new stake in shares of Teva Pharmaceutical Industries in the second quarter worth about $1,334,000. Point72 Asset Management L.P. grew its position in shares of Teva Pharmaceutical Industries by 38.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company’s stock worth $21,437,000 after buying an additional 363,217 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $6,825,000. Ritholtz Wealth Management raised its holdings in shares of Teva Pharmaceutical Industries by 269.5% during the third quarter. Ritholtz Wealth Management now owns 41,643 shares of the company’s stock valued at $750,000 after acquiring an additional 30,374 shares in the last quarter. Finally, Diversify Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $640,000. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Stock Performance

TEVA stock opened at $17.12 on Friday. The business’s 50-day moving average is $17.70 and its two-hundred day moving average is $17.30. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.35 and a fifty-two week high of $19.31. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61.

Wall Street Analyst Weigh In

Several research firms have recently commented on TEVA. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Barclays upped their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Finally, StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus price target of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.